The identification of driver oncogenes has provided clinical implications for molecular targeted therapy in NSCLC, particularly for patients harboring EGFR activating mutations [3,4,5,6], BRAF V600E mutations [7], and oncogenic rearrangements in ALK [8,9,10,11,12,13], ROS1 [13,14] and RET [15,16]. Here, ALK is linked to non-small cell lung carcinoma.